Emerson Electric Co. EMR recently announced that it has completed the acquisition of Fluxa. The financial terms of the transaction were kept under wraps.
Shares of Emerson declined 1.2% yesterday, ending the trading session at $79.5.
Based in Glendale, CA, Fluxa is a pioneer in the life sciences industry, which uses state-of-the-art technology to reduce the time-to-market for new drugs and therapies by collaborating with the drug manufacturing companies. The acquired entity was founded in 2017.
Inside the Headlines
The technology and software provided by Fluxa speeds up the availability of latest drugs, vaccines and therapies for critical illness. The buyout will enable Emerson to leverage Fluxa’s PKM software coupled with its DeltaV control system and life sciences automation software to provide customers with a comprehensive line of solutions for developing new drugs.
The addition of Fluxa complements Emerson’s software and solutions portfolio. This acquisition will help the latter deliver lifesaving therapy and medicines to patients in less time. It’s worth mentioning that Emerson also invested in Fluxa’s equity in 2021.
Zacks Rank, Price Performance and Estimate Trend
Emerson, with a $47.2-billion market capitalization, currently carries a Zacks Rank #3 (Hold). EMR stands to benefit from strength across its end markets and a robust backlog level in the quarters ahead. However, woes related to supply chain, labor and logistics might weigh on it in the near term.
Image Source: Zacks Investment Research
In the past six months, the stock has lost 13.3% compared with the industry’s decline of 26.4%.
In the past 60 days, the Zacks Consensus Estimate for EMR’s earnings has moved up 1.6% to $5.06 for fiscal 2022 (ending September 2022), while the same for fiscal 2023 (ending September 2023) has been raised 0.9% to $5.42.
Stocks to Consider
Some better-ranked stocks in the Industrial Products sector are Greif Inc. GEF, Myers Industries MYE and Titan International TWI, each flaunting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here
Greif has an estimated earnings growth rate of 36% for the current year. In the past 60 days, the Zacks Consensus Estimate for current-year earnings has been revised 17% upward.
Greif pulled off a trailing four-quarter earnings surprise of 22.9%, on average. GEF’s shares have gained 4.4% in the past six months.
Myers Industries has an expected earnings growth rate of 67% for 2022. The Zacks Consensus Estimate for the current year’s earnings has moved up 15% in the past 60 days.
MYE has a trailing four-quarter earnings surprise of 20.1%, on average. Myers Industries’ shares have increased 15.2% over the past six months.
Titan International has an estimated earnings growth rate of 165% for the current year. In the past 60 days, the Zacks Consensus Estimate for current-year earnings has been revised 55% upward.
Titan International pulled off a trailing four-quarter earnings surprise of 56.4%, on average. The stock has surged 37% in six months.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Emerson Electric Co. (EMR): Free Stock Analysis Report
Titan International, Inc. (TWI): Free Stock Analysis Report
Greif, Inc. (GEF): Free Stock Analysis Report
Myers Industries, Inc. (MYE): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
